Keji Pharmaceutical announced that CT1190B, a generic CAR-T cell product targeting CD19/CD20, is used to treat patients with relapsed/refractory large B-cell lymphoma who failed at least second-line standard treatment. The first phase I registered clinical trial in China has completed patient infusion; its IIT study results were presented on a poster at the 2026 European Hematology Association annual meeting.

Zhitongcaijing · 2d ago
Keji Pharmaceutical announced that CT1190B, a generic CAR-T cell product targeting CD19/CD20, is used to treat patients with relapsed/refractory large B-cell lymphoma who failed at least second-line standard treatment. The first phase I registered clinical trial in China has completed patient infusion; its IIT study results were presented on a poster at the 2026 European Hematology Association annual meeting.